Inventia Life Science Raises $25M in Series B Funding
- Inventia Life Science, a Sidney, Australia-based world leader in advanced 3D cell cultures for research and clinical purposes, closed a US $25M Series B funding round
- The round was led by Blackbird Ventures with participation from Skip Capital
- Inventia has also announced the launch of its US operations with the appointment of Dwayne Dexter as its Director of US Sales
- Dr. Dexter will be instrumental in growing the pharmaceutical and academic customer base and driving adoption of Inventia’s technology in the US and Canada
- Founded by CEO Dr. Julio Ribeiro Dr. Aidan O’Mahony, Dr. Cameron Ferris and Peter Arthur in 2013, Inventia is creating tools for advanced biomedical discovery
- The company is headquartered in Sydney, Australia
